TESLASCAN
LOE Approachingmangafodipir trisodium
NDAINJECTIONINJECTABLE
Approved
Nov 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TESLASCAN (mangafodipir trisodium) is an injectable contrast agent approved in 1997 for diagnostic imaging procedures. It is a manganese-based contrast medium used to enhance MRI imaging of the hepatobiliary system and pancreas. The drug works as a paramagnetic contrast agent that accumulates in hepatocytes, improving visualization of liver lesions and biliary pathology.
LOE Approaching
As a diagnostic agent nearing loss of exclusivity with moderate competitive pressure (30), brand team focus is likely shifting toward retention strategies and operational efficiency rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and an approaching LOE lifecycle stage, TESLASCAN career positions are limited and likely focused on mature product stewardship rather than growth. Professionals joining this team should expect responsibilities centered on margin protection, compliance, and managed decline rather than expansion or innovation.
Brand ManagerMedical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.